source
- Boehringer Ingelheim pauses phase 1 trial of BI 3031185 in Japan to investigate safety eventBoehringer Ingelheim has placed a phase 1 study of its investigational oral small‑molecule candidate BI 3031185 on voluntary hold after a safety event was reported. The trial, which began in early…
- US allocates $2 billion to faith-based health groups, highlighting shift toward faith-driven capital in global aidThe Trump administration this month announced a nearly $2 billion allocation for faith‑based organizations, the largest such commitment in over two decades. About $1.4 billion is earmarked for hea…